1165876-07-2

Upstream product

• 1165876-15-2 2-(phenylmethyl)-2,3-dihydro-1H-isoindole-4-carbonitrile 
• 5724-56-1 2,3-dimethylbenzonitrile 
• 1165876-20-9 1,1-dimethylethyl 4-cyano-1,3-dihydro-2H-isoindole-2-carboxylate 
• 1159883-00-7 2,3-dihydro-1H-isoindole-4-carbonitrile 
• 3964-57-6 methyl 4-hydroxy-3-chlorobenzoate 
• 213598-07-3 3-chloro-4-isopropoxy-benzoic acid 
• 1165876-23-2 1,1-dimethylethyl 4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxylate 

Downstream Products

• 1165876-27-6 ethyl 3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-isoindol-2-yl]propanoate 
• 1165876-29-8 ethyl 4-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-isoindol-2-yl]butanoate 
• 1165876-08-3 3-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-isoindol-2-yl]propanoic acid 
• 1165876-09-4 4-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-isoindol-2-yl]butanoic acid 

Relevant academic research and scientific papers

Optimization of sphingosine-1-phosphate-1 receptor agonists: Effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles

The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a variety of side effects have been ascribed to its S1P3 receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P1 receptor agonism. Here we describe a study of the tolerance of the S1P1 and S1P3 receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P1 receptor agonists with good selectivity vs S1P3 receptors, efficacy at 1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

OXADIAZOLE DERIVATIVES FOR USE AS S1P1 AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.